The Ipsen Investment Case

Neuroscience Key ongoing clinical-trial highlights Trial Population Levodopa-induced Patients Design Endpoints Status Mesdopetam dyskinesia in Phase llb NCT04435431 140 Parkinson's Mesdopetam or placebo Change in average daily hours of ON-time without troublesome Data anticipated H2 2022 dyskinesia disease IPN59011 Ax Moderate to LONG-SET Phase I/II NCT04736745 IPN10200 Ax LANTIC Phase I/II Dose escalation and dose finding severe upper 424 facial lines versus Dysport or placebo Primary: Safety Secondary: Efficacy Recruiting Moderate to severe upper 424 facial lines NCT04821089 Dose escalation and dose finding versus Dysport or placebo Primary: Safety Secondary: Efficacy Recruiting IPN10200 Tx Adult patients with LANTIMA Phase I/II NCT04752774 upper limb spasticity 209 Dose escalation and dose finding versus Dysport or placebo Primary: Safety Secondary: Efficacy Recruiting IPSEN Innovation for patient care 1. Good 'ON-time' is the time that people living with Parkinson's disease experience improved Parkinsonian symptoms and no dyskinesia. 30

View entire presentation